Published in Vaccine Weekly, May 24th, 2006
According to recent research published in the journal Vaccine, "Beta-amyloid (A-beta) peptide has been proposed to be a causal factor in Alzheimer disease (AD). Currently being investigated, active and passive A-beta-immunotherapy significantly reduce AD plaque deposition, neuritic dystrophy, and astrogliosis in the brains of APP transgenic (APP/Tg) mice. Immunization with A-beta42 formulated in the Th1-type adjuvant QS21 was beneficial for AD patients with significant titers of anti-A-beta antibodies, however, 6% of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.